NASH and Fatty Liver in the era of COVID-19
September 3, 2021
- Liver Diseases
- Overview
- Alcohol-Associated Liver Disease
- Autoimmune Liver Diseases
- Cancer
- Complications of Liver Disease
- Diagnosing Liver Disease
- Fatty Liver Disease (Steatotic Liver Disease)
- Pediatric Liver Information Center
- Overview
- Pediatric Liver Disease
- Alagille Syndrome
- Alpha-1 Antitrypsin Deficiency
- Autoimmune Liver Disease in Children
- Biliary Atresia
- Budd-Chiari Syndrome
- Crigler-Najjar Syndrome
- Galactosemia
- Hepatitis B
- Hepatitis C in Children
- Nonalcoholic Fatty Liver Disease (NAFLD) in Children
- Glycogen Storage Disease Type 1 (von Gierke)
- Primary Sclerosing Cholangitis (PSC) in Children
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Gilbert Syndrome
- Reye's Syndrome
- Wilson Disease
- Parents
- Liver Disease for Teen and Young Adults
- Kids
- Bili the Brave™ Toolkit
- Video Library
- Liver Terminology
- Rare Disease
- Treatment
- Viral Hepatitis
- About Your Liver
- Health and Wellness
- Resource Center
- How You Can Help
- About ALF
- Mission, Impact and History
- Research Awards Program
- People
- Financial Information
- Policies
- Corporate Policies
- Medical Policies
- COVID-19 Alert Policy
- HCV Screening Recommendations from US Preventative Services Task Force
- Hepatitis A Policy
- Hepatitis C Testing Policy
- Incarcerated Persons
- Needle Exchange Policy
- Organ Donation Policy
- Position on the Use and Care of Animals in Research
- Position Statement on Hepatitis A and Vaccination
- Careers
- Contact Us
NASH & Fatty Liver Disease in the Time of COVID-19 for healthcare professionals featuring Dr. Michael Charlton, University of Chicago, Dr. Mary Rinella, Northwestern Medicine and moderated by Dr. Rocky Yapp, Amita Health/Good Samaritan Hospital.
This program was recorded on September 1, 2020.
Last updated on December 1st, 2022 at 04:50 pm